WASHINGTON, D.C. - Merck & Co. Inc. on Nov. 20 urged the U.S. Supreme Court to grant review of both its challenge to a Third Circuit U.S. Court of Appeals ruling and the Federal Trade Commission's challenge to an 11th Circuit U.S. Court of Appeals ruling in Federal Trade Commission v. Watson Pharmaceuticals, Inc., et al. and to set them for parallel briefing and oral argument because both cases present the issue of the appropriate antitrust standard for evaluating settlements involving reverse payments from name-brand drug manufacturers to generic challengers (Merck & Co., Inc. v. Louisiana Wholesale Drug Co., Inc., et al., No. 12-245, U.S. Sup.).